SpectraCure treats first patient in Cologne in prostate cancer trial

• SpectraCure announced its first patient treatment in Cologne on Nov. 2, 2026, expanding its trial of photodynamic therapy for localized prostate cancer.
• The treatment involved the trial's third patient; the first two received treatment at Memorial Sloan Kettering Cancer Center in New York.
• Initial findings reported in the announcement showed treatment effects consistent with expectations for the low starting light dose.
• The trial is proceeding with gradual dose increases under its protocol, evaluating the therapy as a first-line treatment for previously untreated patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpectraCure AB (publ) published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.